Editorial: The Development of New Classes of Hypoxia Mimetic Agents for Clinical Use

Editorial: The Development of New Classes of Hypoxia Mimetic Agents for Clinical Use

Bibliographic Details
Main Authors:	Ruoli Chen, Nicholas Forsyth
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-06-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	hypoxia inducible factor inhibitor 2 oxogluterate hypoxia mimetic agents prolyl hydroxylase (PHD)
Online Access:	https://www.frontiersin.org/article/10.3389/fcell.2019.00120/full

Similar Items

Rank Order of Small Molecule Induced Hypoxiamimesis to Prevent Retinopathy of Prematurity
by: George Hoppe, et al.
Published: (2020-06-01)

Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors
by: Ruoli Chen, et al.
Published: (2018-10-01)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020-07-01)

Hypoxia Mimetic Agents for Ischemic Stroke
by: Charles K. Davis, et al.
Published: (2019-01-01)

Differential roles for the oxygen sensing enzymes PHD1 and PHD3 in the regulation of neutrophil metabolism and function [version 2; peer review: 1 approved, 3 approved with reservations]
by: Tyler Morrison, et al.
Published: (2024-09-01)

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study
by: Yudian Wang, et al.
Published: (2024-01-01)

Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair
by: Shaoqun Shu, et al.
Published: (2019-02-01)

MYC overrides HIF-1α to regulate proliferating primary cell metabolism in hypoxia
by: Courtney A Copeland, et al.
Published: (2023-07-01)

Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment
by: Sundary Sormendi, et al.
Published: (2018-01-01)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
by: So Yeon Kim, et al.
Published: (2015-11-01)

Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure
by: Mayu Yazaki, et al.
Published: (2024-01-01)

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
by: Junlan Yang, et al.
Published: (2023-03-01)

mRNA expression profile of selected oxygen sensing genes in the lung during recovery from chronic hypoxia
by: Alice Panariti, et al.
Published: (2013-01-01)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease
by: Piotr Bartnicki
Published: (2024-08-01)

Advances of Hypoxia and Lung Cancer
by: Xuebing LI, et al.
Published: (2013-04-01)

Efficacy of novel drugs hypoxia inducible factor prolyl hydroxylase inhibitor in therapy of posttransplant anemia. A review
by: Piotr Pawlowski, et al.
Published: (2024-08-01)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
by: Ishii T, et al.
Published: (2021-02-01)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
by: Jie Lun, et al.
Published: (2023-05-01)

Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review
by: Wei Zhang, et al.
Published: (2024-12-01)

Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation
by: Young-In Kim, et al.
Published: (2021-01-01)

Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence
by: Long-Guang Zhang, et al.
Published: (2024-08-01)

Construction of a recombinant eukaryotic expression vector containing PHD3 gene and its expression in HepG2 cells
by: Liang Qi-Lian, et al.
Published: (2012-08-01)

Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1α
by: Molly E. Ogle, et al.
Published: (2012-02-01)

A genetically encoded biosensor for visualising hypoxia responses in vivo
by: Tvisha Misra, et al.
Published: (2017-02-01)

Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report
by: Nobuaki Ariyoshi, et al.
Published: (2024-03-01)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
by: Chintala Sreenivasulu, et al.
Published: (2012-07-01)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023-11-01)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
by: Hanxue Zhao, et al.
Published: (2023-12-01)

Metabolic Regulation of Hypoxia-Inducible Transcription Factors: The Role of Small Molecule Metabolites and Iron
by: Peter S. J. Bailey, et al.
Published: (2018-05-01)

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

L-mimosine and hypoxia can increase angiogenin production in dental pulp-derived cells
by: Klara Janjić, et al.
Published: (2017-05-01)

Low Oxygen Stress During Early Development Influences Regulation of Hypoxia-Response Genes in Farmed Atlantic Salmon (Salmo salar)
by: Tara Kelly, et al.
Published: (2020-09-01)

The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review
by: Yousuf Abdulkarim Waheed, et al.
Published: (2024-12-01)

Human prolyl hydroxylase domain 2 reacts with O2 and 2-oxoglutarate to enable formation of inactive Fe(III).2OG.hypoxia-inducible-factor α complexes
by: Giorgia Fiorini, et al.
Published: (2024-10-01)

Long-Term Environmental Hypoxia Exposure and Haematopoietic Prolyl Hydroxylase-1 Deletion Do Not Impact Experimental Crohn’s Like Ileitis
by: Cara De Galan, et al.
Published: (2021-09-01)

The Prolyl Hydroxylase Domain 2 (PHD2) Deficiency Enhances Maximal Exercise Capacity
by: Junchul Shin
Published: (2024-02-01)

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis
by: Qiyan Zheng, et al.
Published: (2023-04-01)

Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis
by: Song Ren, et al.
Published: (2024-07-01)

Targeting hypoxia-inducible factor-1 alpha suppresses Helicobacter pylori-induced gastric injury via attenuation of both cag-mediated microbial virulence and proinflammatory host responses
by: Jennifer M. Noto, et al.
Published: (2023-12-01)